efgartigimod alfa-fcab news

All news on efgartigimod alfa-fcab (also known as VYVGART): plants, production capacities, investments and involved companies.

27 July 2026

argenx to acquire Forte Biosciences, adding anti‑CD122 candidate FB102

FB102 shows Phase 1b proof in vitiligo and celiac; Phase 2 in celiac expected H2 2026. Acquisition executed as $77/share cash tender offer; close targeted Q3 2026.

Who will be producing efgartigimod alfa-fcab in the future?

Find out with chemXplore Alpha

Learn more